Cambridge Healthtech Institute’s inaugural

Targeted Radioligand Therapies

Precision Medicine for Cancer

January 14-15, 2025


Targeted radiotherapies, also known as radioligand therapies or molecular radiotherapy, represent a promising frontier in cancer treatment. By combining the specificity of targeted molecules with the potency of radioisotopes, these therapies offer the potential for precise and effective cancer cell elimination while minimizing damage to healthy tissues. At Cambridge Healthtech Institute's Targeted Radioligand Therapies track, we will explore the latest advancements, challenges, and opportunities in this rapidly evolving field, fostering collaborations among researchers, clinicians, and industry leaders to drive the development of these innovative treatments. Attendees will gain insights into innovative targeting mechanisms, radioisotope selection, emerging targets, clinical updates, combination strategies, and logistics and supply chain challenges, culminating in discussions to accelerate the translation of these precision therapies to the clinic.


Novel Targeting Mechanisms and Vectors

  • Peptides, antibodies, and small molecules for targeted delivery
  • Alternative scaffolds: DARPins, affibodies, bicycles, and nanobodies
  • Bispecific and multispecific approaches
  • Strategies for improving tumor penetration and binding affinity

Emerging Targets and Indications

  • Exploration of novel targets beyond PSMA and somatostatin receptors
  • Expanding applications to different cancer types (e.g., breast, lung, glioblastoma)
  • Potential for non-oncology indications

Radiochemistry, Radiobiology and Isotope Landscape

  • Alpha vs Beta emitters, and emerging isotopes
  • Advancements in radiolabeling techniques and radiochemistry
  • Mechanisms of radiation-induced cell death and tumor microenvironment modulation
  • Strategies for enhancing therapeutic efficacy and overcoming resistance

Clinical Trials, Regulatory Landscape and Patient Management

  • Ongoing clinical trials for various cancer types (e.g., prostate, neuroendocrine tumors)
  • Regulatory considerations and approval pathways
  • Patient selection, dosimetry, and treatment planning
  • Combination Strategies - radioligand therapies combined with immunotherapy, chemotherapy, or targeted agents
  • Overcoming resistance mechanisms and tumor heterogeneity
  • Toxicity management

Theranostics and Companion Diagnostics

  • Integration of diagnostic imaging and targeted therapy
  • Development of companion diagnostics for patient stratification
  • Biomarkers for predicting treatment response
  • Personalized dosimetry and treatment planning

Manufacturing and Supply Chain Considerations

  • Radioisotope supply chain and availability challenges
  • Radiopharmaceutical production and quality control
  • Logistics and distribution challenges for short-lived radioisotopes


The deadline for priority consideration is June 28, 2024.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Opportunities for Participation:


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute



For sponsorship information, please contact:


Companies A-K

Jason Gerardi

Sr. Manager, Business Development

Cambridge Healthtech Institute

Phone: +1 781-972-5452



Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: +1 781-972-1340